SHE NOTIFIED THE PATIENTS ON MAY 2ND. THE UNIVERSITY BACKED APHELION PHARMA. SHE HAD SIGNED THE AGREEMENT HERSELF.

Dr. Miriam Tessier chose to notify twelve clinical trial participants of dangerous findings regarding liver fibrosis despite legal threats from Aphelion Pharmaceuticals. Her decision to bypass corporate confidentiality put her career at risk, revealing severe flaws in how patient safety was prioritized.